filmov
tv
Immunogenicity Does Not Automatically Guarantee High Efficacy: S Srinivasan On Covaxin Approval Row
Показать описание
S Srinivasan, Co-Convenor, All India Drug Action Network speaks to India Today on the controversy over the approval for Bharat Biotech's coronavirus vaccine, Covaxin. Srinivasan said that the immunogenicity does not automatically guarantee high efficacy of the drug.
#Covaxin #Coronavirus #CovidVaccine
Subscribe to India Today for NEW VIDEOS EVERY DAY and make sure to enable Push Notifications so you'll never miss a new video.
All you need to do is PRESS THE BELL ICON next to the Subscribe button!
India Today TV is India's leading English News Channel. India Today YouTube channel offers latest news videos on Politics, Business, Cricket, Bollywood, Lifestyle, Auto, Technology, Travel, Entertainment and a lot more.
Stay tuned for latest updates and in-depth analysis of news from India and around the world!
#Covaxin #Coronavirus #CovidVaccine
Subscribe to India Today for NEW VIDEOS EVERY DAY and make sure to enable Push Notifications so you'll never miss a new video.
All you need to do is PRESS THE BELL ICON next to the Subscribe button!
India Today TV is India's leading English News Channel. India Today YouTube channel offers latest news videos on Politics, Business, Cricket, Bollywood, Lifestyle, Auto, Technology, Travel, Entertainment and a lot more.
Stay tuned for latest updates and in-depth analysis of news from India and around the world!
0:05:52
Immunogenicity Does Not Automatically Guarantee High Efficacy: S Srinivasan On Covaxin Approval Row
0:52:05
Timothy Hickling: Immunogenicity of biotherapeutics: why do we care and where do we stand
0:08:08
Predicting and Taming Immunogenicity: Complex Biologic Considerations
0:00:26
Are You Biosimilar Familiar? Immunogenicity
0:52:25
Five Ways to Control Your Critical Antibody Reagents and Avoid Bioanalytical Assay Failure
0:36:12
To Boost or Not to Boost: What Does the Evidence Tell Us?
1:05:05
Predicting and Taming Immunogenicity: Strategies for your Biologic Drug
0:20:06
Non-clinical Evaluation of Immunogenicity Risk of Generic Complex Peptide Products
0:00:52
Why Do We Develop Antinuclear Antibodies (ANA)
1:00:06
Generating and Validating Critical Antibody Reagents
0:17:31
FDA EMA clinical immunogenicity safety assessments first video
0:25:08
Mike Zimmer: Engineering a less immunogenic bacterial protease for treatment of IgA Nephropathy
0:23:07
Model Informed Drug Development Approaches for Immunogenicity Assessments Workshop
0:41:31
Jeremy Fry: An integrated approach to managing immunogenicity risk and drug immune modulation
0:54:59
Jeremy Fry: Mastering immunogenicity: Tools and technologies
0:20:52
Model Informed Drug Development Approaches for Immunogenicity Assessments Workshop
1:05:40
ESGCT e-School: Immunogenicity - the challenge of our own security system
1:04:21
2023 User Workshop – 2.4 – T Cell Class II Tools & Section 1 Q&A
0:25:32
Amy Rosenberg: Immunogenicity in the Time of COVID-19
0:45:14
Jeremy Fry: Tools and technologies for comprehensive immunogenicity risk management
1:00:00
Using an unbiased drug discovery platform to uncover a novel immunogenic cell death
0:52:43
Strategies to Improve Immunogenicity of Vaccines in Immunosuppressed Patients, with Dr. Lora Thomas
1:00:29
Autoimmunity to extracellular DNA by Dr. Boris Reizis
0:39:34
February 2015 ACIP-Meningingococcal Vaccines
Комментарии